Aeras Welcomes David Blumberg to its Board of Directors

Rockville, MD, July 20, 2015 – David L. Blumberg, M.B.A., an expert in the life sciences industry, recently joined Aeras’s Board of Directors. He has more than 20 years of business and consulting experience across the life sciences continuum, including large global, specialty, and generic pharmaceuticals, biotech, and medical devices and products.

“We are delighted that David is bringing his extensive expertise to the Aeras Board,” said Board Chair Lota S. Zoth. “David’s vast experience advising clients in the life sciences will be a highly valuable asset for the organization as we seek to fulfill our mission.”

Mr. Blumberg recently retired from KPMG where he led their U.S. Pharmaceuticals and Life Sciences Advisory practice. Previously, David was the Executive Vice President of Professional Services and Customer Support of a public software company that specializes in contract and demand management for life sciences corporations. He spent several years at Accenture, where he served as lead partner for the Pharmaceutical and Medical Products Industries and led one of the corporation’s largest account relationships.

Mr. Blumberg has an M.B.A. from The Wharton School and a B.S. degree in mechanical engineering from Ohio State University. He is a guest lecturer at The Wharton School, the Harvard Business School and at the New York Institute of Technology. Mr. Blumberg also serves on the Board of Advisors for the Vagelos Life Sciences and Management Program at The Wharton School and the University of Pennsylvania.

About Aeras

Aeras is a nonprofit, global biotech organization developing new tuberculosis vaccines for the world, in partnership with other biotech, pharmaceutical, and academic organizations. Aeras has a staff of more than 100 people from countries around the world, and has offices in the U.S., Africa, and Asia. Aeras is funded primarily by the Bill & Melinda Gates Foundation and European donor governments. Support also is received from the U.S. government as well as from partnerships and collaborations with universities and pharmaceutical companies.

About the Aeras Board of Directors

Aeras is grateful to the members of its Board of Directors for their leadership and international expertise across a broad spectrum of backgrounds:

Lota S. Zoth, Former Sr. VP and CFO of MedImmune, Inc.; Barry Bloom, Ph.D., Distinguished Service Professor at Harvard University; Jim Connolly, Former President and CEO of Aeras; Marja Esveld, M.Sc., Sr. Advisor, Research and Innovation, Ministry of Health, The Netherlands; Thomas G. Evans, M.D., Aeras CEO; Marian Eslie Jacobs, former Dean and Emeritus Professor of Paediatrics and Child Health Faculty of Sciences at the University of Cape Town; Michel Kazatchkine, United Nations Secretary-General’s Special Envoy on HIV/AIDS in Eastern Europe and Central Asia; Wayne F. Pisano, President and CEO of VaxInnate; Regina Rabinovich, M.D., M.P.H., Exxon Mobil Malaria Scholar in Residence, Harvard School of Public Health; and Gerd Zettlmeissl, Ph.D., Former CEO of Intercell AG.